{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,13]],"date-time":"2026-04-13T17:06:43Z","timestamp":1776100003763,"version":"3.50.1"},"reference-count":39,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2027,2,26]],"date-time":"2027-02-26T00:00:00Z","timestamp":1803600000000},"content-version":"am","delay-in-days":331,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/100000050","name":"National Heart Lung and Blood Institute","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000050","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["ajconline.org","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["The American Journal of Cardiology"],"published-print":{"date-parts":[[2026,4]]},"DOI":"10.1016\/j.amjcard.2026.01.015","type":"journal-article","created":{"date-parts":[[2026,2,4]],"date-time":"2026-02-04T00:13:27Z","timestamp":1770164007000},"page":"56-63","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Identifying Subclinical Transthyretin Cardiac Amyloidosis in V142I TTR Carriers: Design, Rationale, and Methods of the VISTA (Variant Imaging of Subclinical Transthyretin Amyloidosis) Study"],"prefix":"10.1016","volume":"264","author":[{"given":"Artrish","family":"Jefferson","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Julia","family":"Kozlitina","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Vlad G.","family":"Zaha","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mazen","family":"Hanna","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Deborah","family":"Kwon","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Andrew J.","family":"Einstein","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lori R.","family":"Roth","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Markey","family":"McNutt","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Brandon","family":"Hathorn","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lorena","family":"Saelices","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lauren","family":"Phillips","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mathew S.","family":"Maurer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"W. H. Wilson","family":"Tang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michael","family":"Nelson","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2400-3196","authenticated-orcid":false,"given":"Justin L.","family":"Grodin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"22","key":"10.1016\/j.amjcard.2026.01.015_bib0001","doi-asserted-by":"crossref","first-page":"2872","DOI":"10.1016\/j.jacc.2019.04.003","article-title":"Transthyretin amyloid Cardiomyopathy: JACC state-of-the-art review","volume":"73","author":"Ruberg","year":"2019","journal-title":"J Am Coll Cardiol"},{"issue":"7","key":"10.1016\/j.amjcard.2026.01.015_bib0002","doi-asserted-by":"crossref","first-page":"733","DOI":"10.1038\/gim.2016.200","article-title":"Transthyretin VI (pV142I)* cardiac amyloidosis: an age-dependent autosomal dominant cardiomyopathy too common to be overlooked as a cause of significant heart disease in elderly African Americans","volume":"19","author":"Buxbaum","year":"2017","journal-title":"Genet Med"},{"issue":"3","key":"10.1016\/j.amjcard.2026.01.015_bib0003","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1016\/j.cardfail.2021.09.015","article-title":"Clinical implications of the amyloidogenic V122I transthyretin variant in the general population","volume":"28","author":"Kozlitina","year":"2022","journal-title":"J Card Fail"},{"issue":"21","key":"10.1016\/j.amjcard.2026.01.015_bib0004","doi-asserted-by":"crossref","first-page":"1824","DOI":"10.1001\/jama.2024.4467","article-title":"Cardiovascular burden of the V142I transthyretin variant","volume":"331","author":"Selvaraj","year":"2024","journal-title":"Jama"},{"issue":"14","key":"10.1016\/j.amjcard.2026.01.015_bib0005","doi-asserted-by":"crossref","first-page":"1368","DOI":"10.1001\/jama.2022.2896","article-title":"Association of transthyretin Valle variant with incident heart failure among black individuals","volume":"327","author":"Parcha","year":"2022","journal-title":"Jama"},{"issue":"1","key":"10.1016\/j.amjcard.2026.01.015_bib0006","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1056\/NEJMoa1404852","article-title":"The amyloidogenic VI transthyretin variant in elderly black Americans","volume":"372","author":"Quarta","year":"2015","journal-title":"N Engl J Med"},{"key":"10.1016\/j.amjcard.2026.01.015_bib0007","doi-asserted-by":"crossref","DOI":"10.1161\/CIRCGEN.124.004911","article-title":"Risk for heart failure and atrial fibrillation across the lifespan for carriers of the amyloidogenic p.VTTR variant","author":"Grodin","year":"2025","journal-title":"Circ Genom Precis Med"},{"issue":"5","key":"10.1016\/j.amjcard.2026.01.015_bib0008","doi-asserted-by":"crossref","first-page":"864","DOI":"10.1016\/j.ahj.2010.02.006","article-title":"Significance of the amyloidogenic transthyretin Valile allele in African Americans in the arteriosclerosis risk in Communities (ARIC) and Cardiovascular Health (CHS) studies","volume":"159","author":"Buxbaum","year":"2010","journal-title":"Am Heart J"},{"key":"10.1016\/j.amjcard.2026.01.015_bib0009","first-page":"15","volume":"1","author":"Madu","year":"2023"},{"issue":"4","key":"10.1016\/j.amjcard.2026.01.015_bib0010","first-page":"372","article-title":"Ethnic distribution of amyloidosis: an autopsy study","volume":"2","author":"Buck","year":"1989","journal-title":"Mod Pathol"},{"issue":"22","key":"10.1016\/j.amjcard.2026.01.015_bib0011","doi-asserted-by":"crossref","first-page":"2191","DOI":"10.1001\/jama.2019.17935","article-title":"Association of the VI hereditary transthyretin amyloidosis genetic variant with heart failure among individuals of African or Hispanic\/Latino ancestry","volume":"322","author":"Damrauer","year":"2019","journal-title":"JAMA"},{"issue":"1","key":"10.1016\/j.amjcard.2026.01.015_bib0012","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1161\/CIRCULATIONAHA.118.038169","article-title":"Natural history, quality of life, and outcome in cardiac transthyretin amyloidosis","volume":"140","author":"Lane","year":"2019","journal-title":"Circulation"},{"issue":"1","key":"10.1016\/j.amjcard.2026.01.015_bib0013","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1056\/NEJMoa2409134","article-title":"Vutrisiran in patients with transthyretin amyloidosis with cardiomyopathy","volume":"392","author":"Fontana","year":"2025","journal-title":"N Engl J Med"},{"issue":"11","key":"10.1016\/j.amjcard.2026.01.015_bib0014","doi-asserted-by":"crossref","first-page":"1007","DOI":"10.1056\/NEJMoa1805689","article-title":"ATTR-ACT Study Investigators, Tafamidis treatment for patients with transthyretin Amyloid cardiomyopathy","volume":"379","author":"Maurer","year":"2018","journal-title":"N Engl J Med"},{"issue":"22","key":"10.1016\/j.amjcard.2026.01.015_bib0015","doi-asserted-by":"crossref","first-page":"1657","DOI":"10.1161\/CIRCULATIONAHA.122.060852","article-title":"Impact of earlier diagnosis in cardiac ATTR amyloidosis over the course of 20 years","volume":"146","author":"Ioannou","year":"2022","journal-title":"Circulation"},{"issue":"2","key":"10.1016\/j.amjcard.2026.01.015_bib0016","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1056\/NEJMoa2305434","article-title":"ATTRibute-CM Investigators., Efficacy and safety of acoramidis in transthyretin amyloid cardiomyopathy","volume":"390","author":"Gillmore","year":"2024","journal-title":"N Engl J Med"},{"issue":"1","key":"10.1016\/j.amjcard.2026.01.015_bib0017","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1080\/13506129.2022.2091985","article-title":"Efficacy and safety of vutrisiran for patients with hereditary transthyretin-mediated amyloidosis with polyneuropathy: a randomized clinical trial","volume":"30","author":"Adams","year":"2023","journal-title":"Amyloid"},{"issue":"24","key":"10.1016\/j.amjcard.2026.01.015_bib0018","doi-asserted-by":"crossref","first-page":"2404","DOI":"10.1161\/CIRCULATIONAHA.116.021612","article-title":"Nonbiopsy diagnosis of cardiac transthyretin amyloidosis","volume":"133","author":"Gillmore","year":"2016","journal-title":"Circulation"},{"issue":"6","key":"10.1016\/j.amjcard.2026.01.015_bib0019","doi-asserted-by":"crossref","first-page":"1299","DOI":"10.1016\/j.jcmg.2020.03.010","article-title":"Native T1 mapping, extracellular volume mapping, and late gadolinium enhancement in cardiac amyloidosis: a meta-analysis","volume":"13","author":"Pan","year":"2020","journal-title":"JACC Cardiovasc Imaging"},{"issue":"12","key":"10.1016\/j.amjcard.2026.01.015_bib0020","doi-asserted-by":"crossref","first-page":"1473","DOI":"10.1016\/j.amjcard.2004.02.058","article-title":"The Dallas Heart Study: a population-based probability sample for the multidisciplinary study of ethnic differences in cardiovascular health","volume":"93","author":"Victor","year":"2004","journal-title":"Am J Cardiol"},{"issue":"2","key":"10.1016\/j.amjcard.2026.01.015_bib0021","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1111\/jns5.12059","article-title":"QOL-DN:validation of a patient reported outcome measure in transthyretin familial amyloid polyneuropathy","volume":"19","author":"Vinik","year":"2014","journal-title":"J Peripher Nerv Syst"},{"issue":"3","key":"10.1016\/j.amjcard.2026.01.015_bib0022","doi-asserted-by":"crossref","first-page":"713","DOI":"10.1007\/s00415-020-09715-5","article-title":"Correction to: analysis of autonomic outcomes in APOLLO, a phase III trial of the RNAi therapeutic patisiran in patients with hereditary transthyretin-mediated amyloidosis","volume":"267","author":"Gonz\u00e1lez-Duarte","year":"2020","journal-title":"J Neurol"},{"issue":"1","key":"10.1016\/j.amjcard.2026.01.015_bib0023","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1186\/s12968-018-0478-3","article-title":"Myocardial native T2 measurement to differentiate light-chain and transthyretin cardiac amyloidosis and assess prognosis","volume":"20","author":"Ridouani","year":"2018","journal-title":"J Cardiovasc Magn Reson"},{"issue":"1","key":"10.1016\/j.amjcard.2026.01.015_bib0024","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1186\/s12968-017-0372-4","article-title":"Dark-blood late gadolinium enhancement without additional magnetization preparation","volume":"19","author":"Holtackers","year":"2017","journal-title":"J Cardiovasc Magn Reson"},{"issue":"5","key":"10.1016\/j.amjcard.2026.01.015_bib0025","doi-asserted-by":"crossref","first-page":"810","DOI":"10.1016\/j.jcmg.2018.02.006","article-title":"Native T1 and extracellular volume in transthyretin amyloidosis","volume":"12","author":"Martinez-Naharro","year":"2019","journal-title":"JACC Cardiovasc Imaging"},{"issue":"1","key":"10.1016\/j.amjcard.2026.01.015_bib0026","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1186\/s12968-017-0419-6","article-title":"The prognostic value of T1 mapping and late gadolinium enhancement cardiovascular magnetic resonance imaging in patients with light chain amyloidosis","volume":"20","author":"Lin","year":"2018","journal-title":"J Cardiovasc Magn Reson"},{"issue":"8","key":"10.1016\/j.amjcard.2026.01.015_bib0027","doi-asserted-by":"crossref","first-page":"10409","DOI":"10.1109\/TPAMI.2023.3243040","article-title":"SequenceMorph: a unified unsupervised learning framework for motion tracking on cardiac image sequences","volume":"45","author":"Ye","year":"2023","journal-title":"IEEE Trans Pattern Anal Mach Intell"},{"issue":"1","key":"10.1016\/j.amjcard.2026.01.015_bib0028","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1186\/1532-429X-13-16","article-title":"Myocardial extravascular extracellular volume fraction measurement by gadolinium cardiovascular magnetic resonance in humans: slow infusion versus bolus","volume":"13","author":"Schelbert","year":"2011","journal-title":"J Cardiovasc Magn Reson"},{"issue":"2","key":"10.1016\/j.amjcard.2026.01.015_bib0029","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1080\/13506129.2024.2322479","article-title":"Circulating transthyretin and retinol binding protein 4 levels among middle-age V122I TTR carriers in the general population","volume":"31","author":"Hendren","year":"2024","journal-title":"Amyloid"},{"issue":"1","key":"10.1016\/j.amjcard.2026.01.015_bib0030","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1007\/s11897-025-00696-y","article-title":"Justin L Grodin 5, Biomarkers in subclinical transthyretin cardiac amyloidosis","volume":"22","author":"Gulati","year":"2025","journal-title":"Curr Heart Fail Rep"},{"issue":"12","key":"10.1016\/j.amjcard.2026.01.015_bib0031","doi-asserted-by":"crossref","first-page":"1137","DOI":"10.1021\/cb100144v","article-title":"Retinol and retinol-binding protein stabilize transthyretin via formation of retinol transport complex","volume":"5","author":"Hyung","year":"2010","journal-title":"ACS Chem Biol"},{"issue":"5","key":"10.1016\/j.amjcard.2026.01.015_bib0032","doi-asserted-by":"crossref","first-page":"356","DOI":"10.1007\/s11897-022-00570-1","article-title":"Update on disease-specific biomarkers in transthyretin cardiac amyloidosis","volume":"19","author":"Hood","year":"2022","journal-title":"Curr Heart Fail Rep"},{"issue":"12","key":"10.1016\/j.amjcard.2026.01.015_bib0033","doi-asserted-by":"crossref","first-page":"1993","DOI":"10.1021\/bi500171j","article-title":"Quantification of transthyretin kinetic stability in human plasma using subunit exchange","volume":"53","author":"Rappley","year":"2014","journal-title":"Biochemistry"},{"issue":"20","key":"10.1016\/j.amjcard.2026.01.015_bib0034","doi-asserted-by":"crossref","first-page":"1911","DOI":"10.1016\/j.jacc.2025.03.542","article-title":"Early increase in serum transthyretin by Acoramidis independently predicts improved survival in TTR amyloid cardiomyopathy","volume":"85","author":"Maurer","year":"2025","journal-title":"J Am Coll Cardiol"},{"issue":"10","key":"10.1016\/j.amjcard.2026.01.015_bib0035","doi-asserted-by":"crossref","first-page":"1015","DOI":"10.1016\/j.jacc.2025.01.008","article-title":"Transthyretin amyloid cardiomyopathy: wherever protein stabilization leads, disease stabilization follows","volume":"85","author":"Grodin","year":"2025","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.amjcard.2026.01.015_bib0036","unstructured":"Monitoring of early disease progression in hereditary transthyretin amyloidosis (MED-hATTR) [Internet]. 2018. Available from: https:\/\/www.clinicaltrials.gov\/study\/NCT03431896."},{"issue":"13","key":"10.1016\/j.amjcard.2026.01.015_bib0037","doi-asserted-by":"crossref","first-page":"1609","DOI":"10.1001\/jama.293.13.1609","article-title":"N-terminal pro-brain natriuretic peptide, C-reactive protein, and urinary albumin levels as predictors of mortality and cardiovascular events in older adults","volume":"293","author":"Kistorp","year":"2005","journal-title":"Jama"},{"issue":"22","key":"10.1016\/j.amjcard.2026.01.015_bib0038","doi-asserted-by":"crossref","first-page":"2494","DOI":"10.1001\/jama.2010.1708","article-title":"Association of serial measures of cardiac troponin T using a sensitive assay with incident heart failure and cardiovascular mortality in older adults","volume":"304","author":"deFilippi","year":"2010","journal-title":"Jama"},{"issue":"6","key":"10.1016\/j.amjcard.2026.01.015_bib0039","doi-asserted-by":"crossref","first-page":"718","DOI":"10.1001\/jamacardio.2020.6623","article-title":"Association of the V122I transthyretin amyloidosis genetic variant with cardiac structure and function in middle-aged black adults: coronary artery risk development in young adults (CARDIA) study","volume":"6","author":"Sinha","year":"2021","journal-title":"JAMA Cardiol"}],"container-title":["The American Journal of Cardiology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0002914926000391?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0002914926000391?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,4,13]],"date-time":"2026-04-13T16:07:43Z","timestamp":1776096463000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0002914926000391"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4]]},"references-count":39,"alternative-id":["S0002914926000391"],"URL":"https:\/\/doi.org\/10.1016\/j.amjcard.2026.01.015","relation":{},"ISSN":["0002-9149"],"issn-type":[{"value":"0002-9149","type":"print"}],"subject":[],"published":{"date-parts":[[2026,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Identifying Subclinical Transthyretin Cardiac Amyloidosis in V142I TTR Carriers: Design, Rationale, and Methods of the VISTA (Variant Imaging of Subclinical Transthyretin Amyloidosis) Study","name":"articletitle","label":"Article Title"},{"value":"The American Journal of Cardiology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.amjcard.2026.01.015","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}